There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xenetic Biosciences (XBIO – Research Report) and Virpax Pharmaceuticals (VRPX – Research Report) with bullish sentiments.
Xenetic Biosciences (XBIO)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Xenetic Biosciences, with a price target of $4.00. The company’s shares closed last Thursday at $0.41.
According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Xenetic Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See the top stocks recommended by analysts >>
Virpax Pharmaceuticals (VRPX)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Virpax Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Thursday at $0.88, close to its 52-week low of $0.61.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Virpax Pharmaceuticals is a Moderate Buy with an average price target of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
